BUZZ-Capricor shares rise as its Duchenne muscular dystrophy drug releases encouraging 24-month data

September 30 - ** Capricor Therapeutics (CAPR.O) shares rose 12.8% to $9.67

** B. Riley Securities stated that 24-month open-label extension study data presented by Capricor at the World Muscle Society Congress in Hiroshima, Japan, met or exceeded its expectations, further supporting the approval outlook of deramiocel for the treatment of Duchenne muscular dystrophy

** The brokerage maintains a "Buy" rating and a price target of $21

** The firm stated these data, based on improvements in upper limb function, further strengthen the case for approval of the drug ahead of the FDA's expected decision on November 22

** In August, after the FDA accepted Capricor's additional 24-month data as the primary amendment to the application, it extended the (link) review period by three months

** As of the previous trading day's close, CAPR shares had fallen 66.6% so far this year

(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translations may contain errors or may not capture required context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for reader convenience. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation features.)